ENTANasdaqPharmaceutical PreparationsFiscal year ends September 30

ENANTA PHARMACEUTICALS INC

Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026

$11.41+0.31 (+2.79%)

Close on Oct 19, 2026

Market cap: $331.92M
P/E (TTM): –
Dividend yield: –

ENANTA PHARMACEUTICALS INC income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-09-30	FY 2024 2024-09-30	FY 2023 2023-09-30	FY 2022 2022-09-30	FY 2021 2021-09-30	FY 2020 2020-09-30	FY 2019 2019-09-30	FY 2018 2018-09-30	FY 2017 2017-09-30	FY 2016 2016-09-30	FY 2015 2015-09-30	FY 2014 2014-09-30	FY 2013 2013-09-30	FY 2012 2012-09-30	FY 2011 2011-09-30
Revenue	65	68	79	86	97	122	205	207	103	88	161	48	32	42	42
Research & Development	107	131	164	165	174	137	142	95	57	40	23	19	17	15	12
General & Administrative	44	58	53	45	33	27	26	23	21	17	14	10	6.18	5.30	5.04
Total Costs & Expenses	151	189	216	210	207	164	168	118	78	57	37	29	–	–	–
Operating Income	-85	-122	-137	-124	-110	-42	37	88	25	31	124	19	9.03	21	25
Interest Expense	7.68	11	5.15	0	0	–	–	–	0.04	0.05	0.01	0.02	0.03	–	3.16
Interest & Investment Income	–	–	–	–	–	–	–	–	2.53	1.74	0.97	0.47	0.25	0.12	0.08
Other Non-Operating Income	1.80	3.90	6.21	1.66	1.99	6.62	8.82	4.79	2.33	1.72	1.31	0.28	0.60	0.11	-1.99
Asset Impairment Charges	0	0	0	0	–	–	–	–	–	–	–	–	–	–	–
Gain (Loss) on Sale of Assets	-0.01	-0.02	-0.15	0	0	–	–	–	–	–	0.03	0.00	0.10	0.06	0.01
Pretax Income	-84	-118	-131	-122	-108	-35	46	93	27	33	125	19	9.63	21	–
Income Tax Expense	-1.66	-1.74	2.82	-0.43	-29	1.15	-0.83	21	9.24	11	46	-15	0	0	0
Net Income incl. Noncontrolling Interests	-82	-116	-134	-122	-79	-36	46	72	18	22	–	–	–	–	–
Net Income	-82	-116	-134	-122	-79	-36	46	72	18	22	79	34	9.63	21	23
Net Income to Common	–	–	–	–	–	–	–	–	–	–	79	34	-6.57	1.37	1.57
EPS (Basic)(per share)	-3.84	-5.48	-6.38	-5.91	-3.92	-1.81	2.37	3.74	0.93	1.14	4.23	1.88	-0.67	1.26	1.40
EPS (Diluted)(per share)	-3.84	-5.48	-6.38	-5.91	-3.92	-1.81	2.21	3.48	0.91	1.13	4.09	1.80	-0.67	1.13	1.32
Shares Outstanding (Basic, Weighted)(shares)	0.02	0.02	0.02	0.02	0.02	0.02	20	19	19	19	19	0.02	9.79	1.09	1.12
Shares Outstanding (Diluted, Weighted)(shares)	0.02	0.02	0.02	0.02	0.02	0.02	21	21	19	19	19	0.02	9.79	2.47	1.86
EBITDA	-81	-119	-135	-121	-106	-38	40	91	27	33	125	19	9.25	21	26

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -90.0%
Net margin: -96.9%
Return on equity, FY2025: -84.6%

Financial strength

Current ratio: 3.76
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 61.7%

Valuation

P/E ratio: –
Price to sales: 5.09
Price to book: 3.28
Dividend yield: –